HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's...
Hence then, the article about akeso announces first patient dose in global registrational trial of cadonilimab pd 1 ctla 4 for pd 1 treatment resistant hepatocellular carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma )
Also on site :
- How Kirsten Storms was written off ‘General Hospital’ after 21 years following ‘mental health crisis’
- Guillermo del Toro said ‘Absolutely No Goddamn AI’ in ‘Pan’s Labyrinth’ 3D Re-Release: ‘We’re Protecting a Lineage of Art’
- Trump bombs in WHCD return and then unleashes on CNN’s Kaitlan Collins and media in jaw dropping hour-long rant